Evidence map›Paper›PMID 25951995›Full record

ArticleStem cell reviews and reports2015

Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood.

Hongyan Zhou, Hector Martinez, Bruce Sun, Aiqun Li, Matthew Zimmer, Nicholas Katsanis, Erica E Davis, Joanne Kurtzberg, Scott Lipnick, Scott Noggle and 2 more

Abstract read
In one paragraph

Article in Stem cell reviews and reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Creation of GMP-Compliant iPSCs From Banked Umbilical Cord Blood.Frontiers in cell and developmental biology · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hongyan ZhouThe New York Stem Cell Foundation Research Institute, New York, NY, 10032, USA, mzhou@nyscf.org.
Hector Martinez
Bruce Sun
Aiqun Li
Matthew Zimmer
Nicholas Katsanis
Erica E Davis
Joanne Kurtzberg
Scott Lipnick
Scott Noggle
Mahendra Rao
Stephen Chang

Funding

Research Project 3P50DK096415 · NIDDK · DUKE UNIVERSITY · PI HAUSER, MICHAEL A · 2012 to 2016
$4.2M
NIDDK NIH HHS P50 DK096415NIDDK NIH HHS P50DK096415
6 · The paper itself

Abstract

Human peripheral blood and umbilical cord blood represent attractive sources of cells for reprogramming to induced pluripotent stem cells (iPSCs). However, to date, most of the blood-derived iPSCs were generated using either integrating methods or starting from T-lymphocytes that have genomic rearrangements thus bearing uncertain consequences when using iPSC-derived lineages for disease modeling and cell therapies. Recently, both peripheral blood and cord blood cells have been reprogrammed into transgene-free iPSC using the Sendai viral vector. Here we demonstrate that peripheral blood can be utilized for medium-throughput iPSC production without the need to maintain cell culture prior to reprogramming induction. Cell reprogramming can also be accomplished with as little as 3000 previously cryopreserved cord blood cells under feeder-free and chemically defined Xeno-free conditions that are compliant with standard Good Manufacturing Practice (GMP) regulations. The first iPSC colonies appear 2-3 weeks faster in comparison to previous reports. Notably, these peripheral blood- and cord blood-derived iPSCs are free of detectable immunoglobulin heavy chain (IGH) and T cell receptor (TCR) gene rearrangements, suggesting they did not originate from B- or T- lymphoid cells. The iPSCs are pluripotent as evaluated by the scorecard assay and in vitro multi lineage functional cell differentiation. Our data show that small volumes of cryopreserved peripheral blood or cord blood cells can be reprogrammed efficiently at a convenient, cost effective and scalable way. In summary, our method expands the reprogramming potential of limited or archived samples either stored at blood banks or obtained from pediatric populations that cannot easily provide large quantities of peripheral blood or a skin biopsy.

Indexed as

Cell DifferentiationCellular ReprogrammingAntigens, CDBiomarkersBlood DonorsCD13 AntigensCell Culture TechniquesCell LineageCryopreservationFetal BloodGene ExpressionGenetic VectorsHumansImmunohistochemistryInduced Pluripotent Stem CellsKruppel-Like Factor 4Antigens, CDBiomarkersCD13 AntigensCD71 antigenKruppel-Like Factor 4Kruppel-Like Transcription FactorsMYC protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycReceptors, TransferrinSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID25951995
PMCPMC4493720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.